REBETOL® (ribavirin) Oral Solution
For more information, please visit our safety data sheets (SDS) page.
2 Results Found
Merck and Roche Establish Strategic Agreements in Fight Against Chronic Hepatitis C
Agreements Focused on Improving Diagnosis, Awareness and Treatment of Chronic Hepatitis C and the Co-Promotion of VICTRELIS™ (boceprevir) Merck (NYSE: MRK), known as MSD outside the United States, announced today that it has entered into agreements with Roche (SIX: RO, ROG; OTCQX: RHHBY), through their respective subsidiaries, to improve treatment, diagnosis and awareness of chronic hepatitis C (HCV) infection in developed and emerging markets. In addition, researchers affiliated with both companies will collaborate to examine novel combinations of marketed and investigational medicines from both organizations to expedite the availability of potential new treatment regimens for patients with HCV. Under the terms of the non-exclusive agreements, Roche will promote VICTRELIS™ (boceprevir) to physicians as part of a triple combination therapy regimen, starting with the United States, and Merck and Roche will work together to educate physicians and patients about hepatitis C,